source
- Inhibrx reports 44% response rate when paired with Keytruda in head-and-neck cancer Phase 2 trialInhibrx Biosciences said its experimental agent INBRX-106 boosted the activity of Merck's Keytruda in a Phase 2 study of a head-and-neck cancer. The combination achieved a 44% overall response rate…
- Astellas revisits gene therapy for XLMTM, offering new hope after earlier setbacksA gene therapy for the rare muscle disorder X‑linked myotubular myopathy (XLMTM) showed mixed results in early trials, with some boys experiencing dramatic recoveries while others died. Astellas P…